Gastric Cancer Stage IV, Peritoneal Metastases
Conditions
Keywords
Gastric cancer, Peritoneal metastasis, Paclitaxel, Sintilimab, Chemotherapy
Brief summary
In this phase 2 study, we combined sintilimab, paclitaxel and S-1 as regimen to treat gastric cancer patients with peritoneal metastasis. We are aim to estimate the efficacy and safety of this regimen in the phase 2 study.
Detailed description
Gastric cancer patients enrolled in this a phase 2 study received sintilimab (200mg intravenously on day 1), paclitaxel (PTX) (20 mg/m2 intraperitoneally and 50 mg/m2 intravenously on days 1 and 8) plus oral S-1 (80 mg/m2 for 14 consecutive days) every 3 weeks. The primary endpoint is 1-year survival rate. Secondary endpoints are adverse events, R0 resection rate, 3-year overall survival (OS), and 3-year progressive free survival. Adverse events are monitored and graded according to the Common Terminology Criteria for Adverse Events version 4.0.
Interventions
DRUGsintilimab, paclitaxel and S-1
Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
Sponsors
Ruijin Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed gastric adenocarcinoma; 2. Peritoneal metastases from gastric cancer requiring definitive diagnosis by laparoscopy, and without gastric outflow tract obstruction and intestinal obstruction; 3. Written (signed) informed consent; 4. Age ≥ 18 years at registration; 5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2; 6. Expected life expectancy \> 3 months; 7. Adequate bone marrow, liver, and renal functions. absolute neutrophil count of ≥1.5×109/L; absolute neutrophil count of ≥1.5×109/L; platelet count of ≥100×109/L; hemoglobin ≥90g/L; bilirubin of \<1.5×upper limit of normal \[ULN\]; alanine aminotransferase and aspartate aminotransferase of \<2.5×ULN; serum creatinine of ≤1.5×ULN; creatinine clearance of \>50 mL/min; TSH ≤1×ULN (if abnormal, T3 and T4 levels should be inspected at the same time, if T3 and T4 levels are normal, they can be included in the group); APTT ≤1.5×ULN and INR ≤1.5×ULN; myocardial enzymogram ≤1×ULN.
Exclusion criteria
1. Confirmed of evidence of distant metastasis other than peritoneal metastasis (e.g.liver metastasis, lung metastasis, para-aortic lymph node metastasis, etc.); 2. During pregnancy, within 28 days of post parturition, or during lactation; 3. Synchronous or metachronous (within 5 years) malignancies. 4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease; 5. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months; 6. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome may affect S-1 absorbers; 7. Known peripheral neuropathy (\> NCI-CTC AE 1). However, patients with only disappearance of deep tendon reflex (DTR) need not be excluded; 8. Patients on steroid or immunosuppressant treatment after organ transplant; 9. Patients with severe uncontrolled recurrent infections or other severe uncontrolled concomitant disease; 10. Moderate or severe renal damage \[creatinine clearance ≤ 50 ml/min\], or serum creatinine \> upper limit of normal (ULN), 115 μmol/L; 11. Known dihydropyrimidine dehydrogenase (DPD) deficiency; 12. Anaphylaxis to paclitaxel or any research drug ingredient. 13. Active autoimmune disease or history of refractory autoimmune disease; Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected; 14. HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA ≥10 copies/ml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time); 15. Steroid or other systemic immunosuppressive therapy was used 14 days before admission, excluding local or physiological doses of systemic glucocorticoids (eg. no more than 10mg/day of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents; 16. Uncontrolled arrhythmia and myocardial infarction within 12 months before admission or active tuberculosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year survival rate | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants experiencing clinical and laboratory adverse events (AEs) | 24 months |
| R0 resection rate | 24 months |
| 3-year overall survival (OS) | 36 months |
| 3-year progressive free survival (PFS) | 36 months |
Countries
China
Contacts
Primary ContactZhongyin Yang, PhD
Backup ContactMin Shi, PhD
Outcome results
None listed